Orally active inhibitor of central and peripheral catechol-O-methyltransferase (COMT). Prepn: K. Bernauer et al., EP 237929; eidem, US 5236952 (1987, 1993 both to Hoffmann-La Roche). Pharmacology: G. Zürcher et al., Adv. Neurol. 53, 497 (1990). HPLC determn in plasma: U. Timm, R. Erdin, J. Chromatogr. 593, 63 (1992). Clinical pharmacokinetics: J. Dingemanse et al., Clin. Pharmacol. Ther. 57, 508 (1995). Clinical evaluation as adjunct to levodopa: P. Limousin et al., Clin. Neuropharmacol. 18, 258 (1995). Review of pharmacology and clinical experience: G. M. Keating, K. A. Lyseng-Williamson, CNS Drugs 19, 165-184 (2005); of safety and efficacy: N. Borges, Expert Opin. Drug Saf. 4, 69-73 (2005).
Antiparkinsonian.
Antiparkinsonian; COMT Inhibitor